News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System at Late Breaking Clinical Trial Session of EuroPCR


5/21/2013 10:47:07 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced excellent six-month clinical trial results today from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System. The positive clinical and angiographic results were presented during the EuroPCR session of “From Late Breaking Trial to Clinical Practice” in Paris today by Alexandre Abizaid, M.D., Ph.D., Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, and co-Principal Investigator of the DESolve Nx trial. The trial represents one of the largest in the industry for bioresorbable scaffolds with angiographic, IVUS, OCT, and MSCT imaging modality follow ups.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES